Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.
Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.
In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.
Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.
Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.
With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.
Aurora Cannabis Inc. (ACB) announced a conference call to discuss its second quarter financial results for fiscal year 2023, scheduled for February 9, 2023, at 5:00 p.m. ET. The financial results will be released after the market closes the same day. CEO Miguel Martin and CFO Glen Ibbott will host the call, which will also include a Q&A session. Investors can access the webcast through the company's investor info page. Aurora continues to serve both medical and consumer markets with a strong brand portfolio, emphasizing its commitment to high-quality cannabis products.
Aurora Cannabis closed the sale of its Aurora Polaris facility, generating approximately $15 million in gross proceeds. This sale is part of the company's ongoing transformation strategy. Following this transaction, Aurora maintains a strong balance sheet with about $320 million in cash and cash equivalents, including $63 million of restricted cash. The company expects to achieve Adjusted EBITDA profitability for the quarter ending December 31, 2022, further solidifying its position in the cannabis industry as a leader in both medical and consumer markets.
Aurora Cannabis (ACB) announced the repurchase of approximately $102.5 million of its convertible senior notes for $99.4 million in cash, achieving a 4.5% discount. This marks a total repurchase of $316.5 million over the past year, leading to annual cash interest savings of $17.4 million. The company reports a strong balance sheet and aims to achieve Adjusted EBITDA profitability by December 31, 2022.
Aurora Cannabis Inc. (ACB) announced the results of its Annual General and Special Meeting held on November 14, 2022. A total of 92,937,078 shares, or 30.93% of issued shares, were represented. All proposed matters were approved, including the election of directors with high approval rates: Miguel Martin received 92.56% support, and Norma Beauchamp 83.50%. Shareholders also approved KPMG as auditors and amendments to several compensation plans. The voting results report is available on SEDAR.
Aurora Cannabis Inc. (NASDAQ: ACB) will discuss its Q1 fiscal year 2023 results on November 10, 2022, at 5:00 p.m. ET. The Company will announce its financial results after market close on the same day. Aurora continues to carve a niche in the cannabis industry, emphasizing quality and innovation in both medical and consumer markets. The conference call will feature CEO Miguel Martin and CFO Glen Ibbott, providing insights into the Company's financial performance and future outlook.
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) has filed its management information circular in preparation for its annual and special meeting of shareholders on November 14, 2022. The materials, now being mailed to shareholders, outline the business to be discussed, voting instructions, and participation details. Key items for voting include the election of nine directors, the appointment of KPMG LLP as auditors, and amendments to the stock option plan. The Board recommends voting in favor of all proposals.
Aurora Cannabis (NASDAQ: ACB) announced a major fall product launch, expanding its portfolio across adult-use and medical markets. The lineup features innovative strains such as Electric Honeydew and Ultra Grape Kush, showcasing unique genetics and high-potency THC levels. The new products include high-potency gummies, flower, and infused pre-rolls. This marks Aurora's most substantial release in over two years, with over 60 new offerings becoming available in October.
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) announced on October 7, 2022, a repurchase of approximately $31.3 million in convertible senior notes, costing $29.8 million in cash, including interest. This transaction aims to reduce the company's debt and annual cash interest costs, yielding annual savings of about $11.9 million. With roughly $380 million in cash and cash equivalents, Aurora's balance sheet remains robust, and the company expects to achieve a positive Adjusted EBITDA run rate by December 31, 2022.
Akanda prepares for its first export shipment of premium cannabis from its Portugal-based Holigen facility to Germany. The company targets a 10% market share in the growing German medical cannabis sector, backed by a supply agreement with Cansativa for 1,000 kilograms of cannabis. This initiative positions Akanda to capitalize on Germany's medical cannabis market, which has seen a 27% increase in imports. Additionally, Akanda has partnered with Cookies to enhance its brand presence and expand into potential adult-use markets in Europe.
FAQ
What is the current stock price of Aurora Cannabis Common Shares (ACB)?
What is the market cap of Aurora Cannabis Common Shares (ACB)?
What is Aurora Cannabis Inc. primarily known for?
Where is Aurora Cannabis Inc. headquartered?
What are some of the brands under Aurora Cannabis?
What recent products has Aurora Cannabis launched?
What is Aurora's financial outlook for 2024?
What significant acquisitions has Aurora made recently?
What certifications do Aurora's production facilities hold?
How does Aurora contribute to the U.S. cannabis market?
What international operations does Aurora have?
How does Aurora ensure the quality of its products?
